Literature DB >> 26624582

Performance Assessment of the Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Method for Rapid Detection of Susceptibility to Ethambutol and Molecular Prediction of Extensively Drug-resistant Tuberculosis in Clinical Isolates of Mycobacterium tuberculosis.

M Arjomandzadegan1, R Nazari2, M R Zolfaghari2, M Taherahmadi2, M Sadrnia3, L P Titov4, A Ahmadi5, M Shojapoor6.   

Abstract

INTRODUCTION: The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was employed for rapid detection of ethambutol (EMB) resistant clinical isolates of Mycobacterium tuberculosis.
MATERIALS AND METHODS: From 182 clinical isolates of M tuberculosis collected from different regions, 103 strains were entered in the investigation. DNA was extracted by Chelex 100 method and PCR was performed using specific primers for embB gene. Polymerase chain reaction products were digested with HaeIII and NlaII restriction endonucleases and the patterns of restriction fragments were analysed. Some randomly selected samples were sequenced.
RESULTS: Out of 103 studied strains, 52 were resistant to EMB. The cases of secondary tuberculosis were 53 (51.50 ± 1.77%), and primary cases 50 (48.50 ± 1.77%; p > 0.05). From 63 extensively drug-resistant (XDR), pre-XDR and multidrug-resistant (MDR) isolates, 27 (87%), 18 (81.8%) and 7 (70%) strains were resistant to EMB, respectively. Results of PCR-RFLP method showed that from 27R EMB XDR isolates, 13 (sensitivity 48% with CI: 0.307, 0.66 and specificity 100%), from 18R EMB pre-XDR strains, 4 (sensitivity 22% with CI: 0.09, 0.45 and specificity 100%) and of 7R EMB MDR, 2 (sensitivity 28% with CI: 0.082, 0.64 and specificity 100%) had mutation in ATG-Met codon 306. Results of sequencing were concordant with RFLP method. Overall, sensitivity of the molecular method was 36.5% (CI: 0.09, 0.45) and specificity 100%. None of the 40 pansusceptible strains was embB306 mutants. Extensively drug-resistant strains had a higher proportion of embB306 mutants (43%) than pre-XDR and MDR isolates (odds ratio 6.78; p < 0.001).
CONCLUSION: Fast detection of susceptibility to EMB drug is possible by PCR-RFLP. The embB306 locus is a candidate marker for rapid prediction of high resistance consisting of MDR and XDR forms to anti-tuberculosis drugs using this method.

Entities:  

Year:  2015        PMID: 26624582      PMCID: PMC4909062          DOI: 10.7727/wimj.2014.022

Source DB:  PubMed          Journal:  West Indian Med J        ISSN: 0043-3144            Impact factor:   0.171


  19 in total

1.  Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis.

Authors:  Wei-Lun Huang; Ting-Lin Chi; Mei-Hua Wu; Ruwen Jou
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

2.  Significance of mutations in embB codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates.

Authors:  Claudia Plinke; Sabine Rüsch-Gerdes; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis.

Authors:  Vo Sy Kiet; Nguyen Thi Ngoc Lan; Duong Duy An; Nguyen Huy Dung; Dai Viet Hoa; Nguyen van Vinh Chau; Nguyen Tran Chinh; Jeremy Farrar; Maxine Caws
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

4.  Detection of ethambutol-resistant Mycobacterium tuberculosis strains by multiplex allele-specific PCR assay targeting embB306 mutations.

Authors:  Igor Mokrousov; Olga Narvskaya; Elena Limeschenko; Tatiana Otten; Boris Vyshnevskiy
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

5.  Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance.

Authors:  Manzour Hernando Hazbón; Miriam Bobadilla del Valle; Marta Inírida Guerrero; Mandira Varma-Basil; Ingrid Filliol; Magali Cavatore; Roberto Colangeli; Hassan Safi; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Amy Davidow; Michael Brimacombe; Clara Inés León; Tania Porras; Mridula Bose; Fernando Chaves; Kathleen D Eisenach; José Sifuentes-Osornio; Alfredo Ponce de León; M Donald Cave; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Global tuberculosis incidence and mortality during 1990-2000.

Authors:  P J Dolin; M C Raviglione; A Kochi
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

7.  Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait.

Authors:  S Ahmad; A-A Jaber; E Mokaddas
Journal:  Tuberculosis (Edinb)       Date:  2007-02-07       Impact factor: 3.131

8.  Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  J C Palomino; H Traore; K Fissette; F Portaels
Journal:  Int J Tuberc Lung Dis       Date:  1999-04       Impact factor: 2.373

9.  Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis.

Authors:  Angela M Starks; Aysel Gumusboga; Bonnie B Plikaytis; Thomas M Shinnick; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

10.  Five-antituberculosis Drug-resistance Genes Detection Using Array System.

Authors:  Yasuo Shimizu; Kunio Dobashi; Yoko Yoshikawa; Shigeki Yabe; Seiichi Higuchi; Yoko Koike; Yoshihiro Mita; Mitsuyoshi Utsugi; Katsuaki Endou; Kouichi Takahashi; Satoru Watanabe; Ryusei Saito; Masatomo Mori
Journal:  J Clin Biochem Nutr       Date:  2008-05       Impact factor: 3.114

View more
  1 in total

1.  Transmission Electron Microscopy of XDR Mycobacterium tuberculosis Isolates Grown on High Dose of Ofloxacin.

Authors:  Mohammad Arjomandzadegan; Maryam Sadrnia; Leonid Titov; Larissa Surkova; Hossein Sarmadian; Reza Ghasemikhah; Hossein Hosseiny
Journal:  Sci Pharm       Date:  2017-02-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.